tradingkey.logo
tradingkey.logo
Search

Baxter International Inc

BAX
Add to Watchlist
22.690USD
-0.110-0.48%
Market hours 09/21, 11:10ET
11.73BMarket Cap
LossP/E TTM

Baxter International Inc (BAX) Revenue Performance

Updated: Jun 30, 2026

Last year, Baxter International Inc generated 4.10B USD for its biggest-performing segment, Infusion Therapies and Technologies. The United States made the largest contribution, accounting for 6.12B USD last year. For the latest quarter, Baxter International Inc reported the revenue of 1.75B USD for the period ending 2026-06-30, which came from the top-performing segment, Infusion Therapies and Technologies. United States contributed the highest revenue, at 1.59B USD.

By Business

Annual
Annual
Quarterly
Infusion Therapies and Technologies
Care and Connectivity Solutions
Injectables and Anesthesia
Advanced Surgery
Front Line Care
Drug Compounding
Other
Chronic Therapies
Acute Therapies
Renal Care
Medication Delivery
Pharmaceuticals
Patient Support Systems
Clinical Nutrition
Acute Theapies
BioPharma Solutions
Surgical Solutions
Other Product Or Services
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Infusion Therapies and Technologies
4.10B(36.47%)
4.10B(38.58%)
3.96B(26.73%)
3.82B(13.89%)
3.84B(16.10%)
--(--)
--(--)
--(--)
Care and Connectivity Solutions
1.91B(17.00%)
1.81B(17.06%)
1.80B(12.15%)
1.79B(6.52%)
142.00M(0.59%)
--(--)
--(--)
--(--)
Injectables and Anesthesia
1.35B(12.02%)
1.37B(12.91%)
1.35B(9.09%)
1.30B(4.75%)
1.39B(5.82%)
--(--)
--(--)
--(--)
Advanced Surgery
1.20B(10.65%)
1.10B(10.38%)
1.05B(7.10%)
998.00M(3.63%)
977.00M(4.09%)
888.00M(7.61%)
877.00M(7.72%)
800.00M(7.19%)
Front Line Care
1.16B(10.32%)
1.14B(10.69%)
1.21B(8.19%)
1.15B(4.18%)
70.00M(0.29%)
--(--)
--(--)
--(--)
Drug Compounding
1.14B(10.15%)
1.04B(9.76%)
902.00M(6.09%)
821.00M(2.99%)
901.00M(3.77%)
--(--)
--(--)
--(--)
Other
381.00M(3.39%)
67.00M(0.63%)
87.00M(0.59%)
177.00M(0.64%)
140.00M(0.59%)
--(--)
--(--)
--(--)
Chronic Therapies
--(--)
--(--)
3.68B(24.86%)
3.71B(13.52%)
3.86B(16.17%)
--(--)
--(--)
--(--)
Acute Therapies
--(--)
--(--)
770.00M(5.20%)
735.00M(2.68%)
820.00M(3.43%)
--(--)
--(--)
--(--)
Renal Care
--(--)
--(--)
--(--)
3.75B(13.64%)
3.90B(16.33%)
3.76B(32.19%)
3.64B(32.03%)
3.66B(32.91%)
Medication Delivery
--(--)
--(--)
--(--)
2.89B(10.50%)
2.88B(12.06%)
2.73B(23.43%)
2.80B(24.63%)
2.67B(23.99%)
Pharmaceuticals
--(--)
--(--)
--(--)
2.13B(7.74%)
2.29B(9.59%)
2.12B(18.19%)
2.15B(18.97%)
2.09B(18.80%)
Patient Support Systems
--(--)
--(--)
--(--)
1.49B(5.41%)
115.00M(0.48%)
--(--)
--(--)
--(--)
Clinical Nutrition
--(--)
--(--)
--(--)
931.00M(3.39%)
964.00M(4.04%)
922.00M(7.90%)
872.00M(7.67%)
877.00M(7.88%)
Acute Theapies
--(--)
--(--)
--(--)
701.00M(2.55%)
782.00M(3.27%)
740.00M(6.34%)
535.00M(4.71%)
517.00M(4.65%)
BioPharma Solutions
--(--)
--(--)
--(--)
644.00M(2.34%)
669.00M(2.80%)
--(--)
--(--)
--(--)
Surgical Solutions
--(--)
--(--)
--(--)
304.00M(1.11%)
27.00M(0.11%)
--(--)
--(--)
--(--)
Other Product Or Services
--(--)
--(--)
--(--)
140.00M(0.51%)
109.00M(0.46%)
508.00M(4.35%)
485.00M(4.27%)
510.00M(4.58%)

By Region

Annual
Annual
Quarterly
United States
International
AMERICAS
Europe,Africa & Middle East (Region)
Asia pacific
FY2025
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
United States
6.12B(54.45%)
5.85B(55.00%)
5.80B(56.00%)
5.77B(57.36%)
4.94B(40.66%)
--(--)
--(--)
5.96B(34.93%)
International
5.12B(45.55%)
4.79B(45.00%)
4.56B(44.00%)
4.29B(42.64%)
7.21B(59.34%)
--(--)
--(--)
--(--)
AMERICAS
--(--)
--(--)
--(--)
--(--)
--(--)
6.07B(51.99%)
6.09B(53.63%)
5.95B(34.89%)
Europe,Africa & Middle East (Region)
--(--)
--(--)
--(--)
--(--)
--(--)
3.13B(26.81%)
2.97B(26.12%)
2.95B(17.27%)
Asia pacific
--(--)
--(--)
--(--)
--(--)
--(--)
2.48B(21.20%)
2.30B(20.24%)
2.20B(12.91%)
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.